SAN ANTONIO, Dec. 9, 2011 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today presented two preclinical studies aimed at producing potent therapeutics for diverse epithelial carcinomas, including breast cancers. Results from these studies were reported at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, which is organized by the Cancer Therapy & Research Center at UT Health Science Center San Antonio, the American Association for Cancer Research, and Baylor College of Medicine.
